Results 41 to 50 of about 53,113 (297)

A multistate model for early decision making in oncology

, 2018
The development of oncology drugs progresses through multiple phases, where after each phase a decision is made about whether to move a molecule forward.
Beyer, Ulrich, Burger, Hans Ulrich, Dejardin, David, Meller, Matthias, Rufibach, Kaspar   +4 more
core   +1 more source

SPECT Imaging of PD-L1 Expression of MDA-MB-231 Tumor Xenograft Mice with 125I-labeled Monoclonal Antibody

Journal of Isotopes
125I-Atezolizumab was synthesized with Iodogen method for monitoring the expression level of PD-L1 in tumors. The influence of reaction time on 125I-labeling efficiency and the stability of 125I-Atezolizumab in PBS and fetal bovine serum were studied ...
Shuhua HE, Yang WANG, Xiaobei ZHENG, Yuxia LIU, Lina JIA, Lan ZHANG   +5 more
doaj   +1 more source

IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Exploratory Analysis of the Phase III Study

Liver Cancer, 2022
Introduction: The Phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC).
Masatoshi Kudo, Richard S. Finn, Peter R. Galle, Andrew X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni   +10 more
doaj   +1 more source

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study [PDF]

, 2018
Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC).
Beckmann, Richard, Garrido, Pilar, Goldman, Jonathan W., Gutierrez, Martin, Hossain, Anwar, Jalal, Shadia, John, William J., Johnston, Erica L., Kambhampati, Siva Rama Prasad, Kelly, Karen, Kim, Edward S., Mahadevan, Daruka, Paz-Ares, Luis G., Provencio, Mariano, Schaefer, Eric, Shaheen, Monte, Turner, P. Kellie   +16 more
core   +2 more sources

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source

Successful treatment with atezolizumab in a haemodialysis patient with large cell neuroendocrine carcinoma

Respirology Case Reports, 2023
In this report, a modified regimen based on IMpower 133 (carboplatin + etoposide + atezolizumab) was administered to a patient diagnosed with large cell neuroendocrine carcinoma (LCNEC) who was concurrently undergoing haemodialysis. Adverse events led to
Ryosuke Imai, Atsushi Kitamura
doaj   +1 more source

Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives [PDF]

, 2016
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with relatively poor prognosis, earlier disease recurrence and higher number of visceral metastases.
ARPINO, GRAZIA, DE PLACIDO, SABINO, GIULIANO, MARIO, SCHETTINI, FRANCESCO   +3 more
core   +1 more source

Elemene Augments the Effects of Anti‐PD‐1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR‐130a‐5p/SPP/MHC‐I Axis

Advanced Science, EarlyView.
Elemene increases SPP expression by competitively binding with miR‐130a‐5p to suppress SPP mRNA degradation. This led to more antigen/MHC‐I complexes being expressed on the cell surface, which consequently facilitated the recognition and killing of HCC cells by CTLs and enhancing the antitumor immune efficacy of anti‐PD‐1.
Menglan Wang, Mengqing Sun, Heng Dong, Xiaoting Zhang, Jingbo Zhang, Zhengguo Zhang, Mengjie Ni, Lina Li, Yunxin Pei, Xiaoyu Chen, Qian Li, Fangtian Bu, Jiacheng Huang, Liangyu Jiang, Zhuting Fang, Xuliang Chen, Jianxiang Chen, Yiting Qiao, Tian Xie   +18 more
wiley   +1 more source

Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody

Thoracic Cancer, 2021
Background Atezolizumab is a programmed death‐ligand 1 (PD‐L1) targeted monoclonal antibody that inhibits PD‐L1 interacting with its receptors PD‐1 and B7‐1, thereby enhancing anticancer immunity.
Naoki Furuya, Makoto Nishino, Kazushige Wakuda, Satoshi Ikeda, Takashi Sato, Ryota Ushio, Shigeru Tanzawa, Masafumi Sata, Kentaro Ito   +8 more
doaj   +1 more source